Search Results

There are 23213 results for: content related to: Phase 2 trial of irinotecan and thalidomide in adults with recurrent anaplastic glioma

  1. UGT1A1 genotype and irinotecan therapy: general review and implementation in routine practice

    Fundamental & Clinical Pharmacology

    Volume 29, Issue 3, June 2015, Pages: 219–237, Marie-Christine Etienne-Grimaldi, Jean-Christophe Boyer, Fabienne Thomas, Sylvie Quaranta, Nicolas Picard, Marie-Anne Loriot, Céline Narjoz, Delphine Poncet, Marie-Claude Gagnieu, Cécile Ged, Franck Broly, Valérie Le Morvan, Régis Bouquié, Marie-Pierre Gaub, Laurent Philibert, François Ghiringhelli, Chantal Le Guellec and Collective work by the Groupe de Pharmacologie Clinique Oncologique (GPCO-Unicancer) and the French Réseau National de Pharmacogénétique Hospitalière (RNPGx)

    Version of Record online : 4 MAY 2015, DOI: 10.1111/fcp.12117

  2. You have free access to this content
    Targeted inhibition of IL-18 attenuates irinotecan-induced intestinal mucositis in mice

    British Journal of Pharmacology

    Volume 171, Issue 9, May 2014, Pages: 2335–2350, R C P Lima-Júnior, H C Freitas, D V T Wong, C W S Wanderley, L G Nunes, L L Leite, S P Miranda, M H L P Souza, G A C Brito, P J C Magalhães, M M Teixeira, F Q Cunha and R A Ribeiro

    Version of Record online : 11 APR 2014, DOI: 10.1111/bph.12584

  3. You have free access to this content
    Heat shock protein 27 is associated with irinotecan resistance in human colorectal cancer cells

    FEBS Letters

    Volume 581, Issue 8, April 17, 2007, Pages: 1649–1656, Dae Hwa Choi, Jin Sook Ha, Won Hyuck Lee, Jeong Kee Song, Gyu Yeol Kim, Jae Hoo Park, Hee Jeong Cha, Byung Ju Lee and Jeong Woo Park

    Version of Record online : 22 MAR 2007, DOI: 10.1016/j.febslet.2007.02.075

  4. You have free access to this content
    Emerging clinical principles on the use of bevacizumab for the treatment of malignant gliomas

    Cancer

    Volume 116, Issue 17, 1 September 2010, Pages: 3988–3999, Marc C. Chamberlain

    Version of Record online : 19 AUG 2010, DOI: 10.1002/cncr.25256

  5. Phase II study of cetuximab with irinotecan for KRAS wild-type colorectal cancer in Japanese patients

    Asia-Pacific Journal of Clinical Oncology

    Tetsuji Terazawa, Hitoshi Nishitani, Ken Kato, Hironobu Hashimoto, Kohei Akiyoshi, Yuriko Ito, Akihiro Nakamoto, Satoru Iwasa, Takako Eguchi Nakajima, Tetsuya Hamaguchi, Yasuhide Yamada and Yasuhiro Shimada

    Version of Record online : 6 AUG 2015, DOI: 10.1111/ajco.12405

  6. You have free access to this content
    Bevacizumab and glioblastoma: Scientific review, newly reported updates, and ongoing controversies

    Cancer

    Volume 121, Issue 7, April 1, 2015, Pages: 997–1007, Kathryn M. Field, Justin T. Jordan, Patrick Y. Wen, Mark A. Rosenthal and David A. Reardon

    Version of Record online : 26 SEP 2014, DOI: 10.1002/cncr.28935

  7. Quantification of the impact of enzyme-inducing antiepileptic drugs on irinotecan pharmacokinetics and SN-38 exposure

    The Journal of Clinical Pharmacology

    Volume 55, Issue 11, November 2015, Pages: 1303–1312, Alexander K. Berg, Jan C. Buckner, Evanthia Galanis, Kurt A. Jaeckle, Matthew M. Ames and Joel M. Reid

    Version of Record online : 26 JUN 2015, DOI: 10.1002/jcph.543

  8. You have full text access to this Open Access content
    Phase I/II study of a 3-week cycle of irinotecan and S-1 in patients with advanced colorectal cancer

    Cancer Science

    Volume 101, Issue 12, December 2010, Pages: 2591–2595, Hitoshi Kusaba, Taito Esaki, Kitaro Futami, Sinnosuke Tanaka, Hiromitsu Fujishima, Kenji Mitsugi, Kenji Sakai, Hiroshi Ariyama, Risa Tanaka, Naoko Kinugawa, Takashi Ueki, Rhuichi Mibu, Eishi Baba, Shuji Nakano and Koichi Akashi

    Version of Record online : 24 SEP 2010, DOI: 10.1111/j.1349-7006.2010.01728.x

  9. Cetuximab increases concentrations of irinotecan and of its active metabolite SN-38 in plasma and tumour of human colorectal carcinoma-bearing mice

    Fundamental & Clinical Pharmacology

    Volume 28, Issue 6, December 2014, Pages: 652–660, Céline Chu, Chadi Abbara, Mahamadou Tandia, Mélanie Polrot, Patrick Gonin, Robert Farinotti and Laurence Bonhomme-Faivre

    Version of Record online : 16 APR 2014, DOI: 10.1111/fcp.12071

  10. Phase II 2-arm trial of the proteasome inhibitor, PS-341 (bortezomib) in combination with irinotecan or PS-341 alone followed by the addition of irinotecan at time of progression in patients with locally recurrent or metastatic squamous cell carcinoma of the head and neck (E1304): A trial of the Eastern Cooperative Oncology Group

    Head & Neck

    Volume 35, Issue 7, July 2013, Pages: 942–948, Jill Gilbert, Ju Whei Lee, Athanassios Argiris, Missak Haigentz Jr., Lawrence Eric Feldman, Minyoung Jang, Pattatheyil Arun, Carter Van Waes and Arlene A. Forastiere

    Version of Record online : 13 JUL 2012, DOI: 10.1002/hed.23046

  11. You have full text access to this OnlineOpen article
    Comet assay measures of DNA damage as biomarkers of irinotecan response in colorectal cancer in vitro and in vivo

    Cancer Medicine

    Volume 4, Issue 9, September 2015, Pages: 1309–1321, Joanna P. Wood, Andrew J. O. Smith, Karen J. Bowman, Anne L. Thomas and George D. D. Jones

    Version of Record online : 23 JUN 2015, DOI: 10.1002/cam4.477

  12. You have free access to this content
    Comparative and cost-effectiveness of oxaliplatin-based or irinotecan-based regimens compared with 5-fluorouracil/leucovorin alone among US elderly stage IV colon cancer patients

    Cancer

    Volume 118, Issue 12, 15 June 2012, Pages: 3173–3181, C. Daniel Mullins, Fei-Yuan Hsiao, Eberechukwu Onukwugha, Naimish B. Pandya and Nader Hanna

    Version of Record online : 21 OCT 2011, DOI: 10.1002/cncr.26613

  13. You have full text access to this Open Access content
    Association between deficient mismatch repair system and efficacy to irinotecan-containing chemotherapy in metastatic colon cancer

    Cancer Science

    Volume 102, Issue 9, September 2011, Pages: 1706–1711, Jeong Eun Kim, Yong Sang Hong, Min-Hee Ryu, Jae-Lyun Lee, Heung Moon Chang, Seok-Byung Lim, Jong Hoon Kim, Se-Jin Jang, Mi-Jung Kim, Chang Sik Yu, Yoon-Koo Kang, Jin Cheon Kim and Tae Won Kim

    Version of Record online : 12 JUL 2011, DOI: 10.1111/j.1349-7006.2011.02009.x

  14. You have free access to this content
    Phase 1 and pharmacokinetic study of concurrent carboplatin and irinotecan in subjects aged 1 to 21 years with refractory solid tumors

    Cancer

    Volume 115, Issue 1, 1 January 2009, Pages: 207–216, Adam S. Levy, Paul A. Meyers, Leonard H. Wexler, Regina Jakacki, Anne Angiolillo, Sarah N. Ringuette, Marvin B. Cohen, Richard Gorlick and Other site principal investigators: Wayne Furman, MD (St. Jude Children's Research Hospital, Memphis, Tennessee); Rochelle Bagatell, MD (University of Arizona Health Sciences Center, Tucson, Arizona); Lori Luchtman-Jones, MD (Washington University School of Medicine, St. Louis, Missouri); Luis Eduardo Garcia, MD (Hospital CIMA, San Jose, Costa Rica); and Eric Sandler, MD (Nemours Children's Clinic, Jacksonville, Florida).

    Version of Record online : 17 DEC 2008, DOI: 10.1002/cncr.23992

  15. Caspase-mediated pro-apoptotic interaction of panaxadiol and irinotecan in human colorectal cancer cells

    Journal of Pharmacy and Pharmacology

    Volume 64, Issue 5, May 2012, Pages: 727–734, Guang-Jian Du, Chong-Zhi Wang, Zhi-Yu Zhang, Xiao-Dong Wen, Jacqueline Somogyi, Tyler Calway, Tong-Chuan He, Wei Du and Chun-Su Yuan

    Version of Record online : 21 FEB 2012, DOI: 10.1111/j.2042-7158.2012.01463.x

  16. You have free access to this content
    Randomized Phase II study of two opposite administration sequences of irinotecan and cisplatin in patients with advanced nonsmall cell lung carcinoma

    Cancer

    Volume 106, Issue 4, 15 February 2006, Pages: 873–880, Ji-Youn Han, Hyeong-Seok Lim, Dae Ho Lee, So Young Ju, Sung Young Lee, Hyae Young Kim, Yong-Hoon Park, Chun Gun Park and Jin Soo Lee

    Version of Record online : 12 JAN 2006, DOI: 10.1002/cncr.21668

  17. Renal Function as a Predictor of Irinotecan-induced Neutropenia

    Clinical Pharmacology & Therapeutics

    Volume 84, Issue 2, August 2008, Pages: 254–262, FA de Jong, JM van der Bol, RHJ Mathijssen, T van Gelder, EAC Wiemer, A Sparreboom and J Verweij

    Version of Record online : 20 FEB 2008, DOI: 10.1038/sj.clpt.6100513

  18. You have full text access to this OnlineOpen article
    Irinotecan plus fluorouracil-based regimen as second or third-line chemotherapy for recurrent or metastatic esophageal squamous cell carcinoma

    Thoracic Cancer

    Volume 7, Issue 2, March 2016, Pages: 246–250, Xi Wang, Xinwei Wang and Jing Huang

    Version of Record online : 25 NOV 2015, DOI: 10.1111/1759-7714.12323

  19. Anti-EGFR Monoclonal Antibodies for Treatment of Colorectal Cancers: Development of Cetuximab and Panitumumab

    The Journal of Clinical Pharmacology

    Volume 52, Issue 2, February 2012, Pages: 128–155, Dr Benoit You and Dr Eric X. Chen

    Version of Record online : 7 MAR 2013, DOI: 10.1177/0091270010395940

  20. You have free access to this content
    Overall survival benefits for irinotecan-containing regimens as first-line treatment for advanced gastric cancer: An updated meta-analysis of ten randomized controlled trials

    International Journal of Cancer

    Volume 132, Issue 2, 15 January 2013, Pages: E66–E73, Wei-Xiang Qi, Zan Shen, Feng Lin, Yuan-Jue Sun, Da-Liu Min, Li-Na Tang, Ai-Na He and Yang Yao

    Version of Record online : 1 SEP 2012, DOI: 10.1002/ijc.27775